|6.53||-0.0200||-0.31%||Vol 183.14K||1Y Perf 163.71%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||-0.03 -0.46%|
|Target Price||8.00||Analyst Rating||Moderate Buy 2.00|
|Potential %||22.51||Finscreener Ranking||★★+ 49.37|
|Insiders Trans % 3/6/12 mo.||-100/-100/60||Value Ranking||★★ 47.81|
|Insiders Value % 3/6/12 mo.||-100/-100/-15||Growth Ranking||★★ 45.85|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/26||Income Ranking||— -|
|Market Cap||260.06M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||87.99||Earnings Date||4th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2021|
|Estimated EPS Next Report||0.01|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||250.67K|
|Avg. Monthly Volume||339.88K|
|Avg. Quarterly Volume||219.29K|
Harvard Bioscience Inc. (NASDAQ: HBIO) stock closed at 6.53 per share at the end of the most recent trading day (a -0.31% change compared to the prior day closing price) with a volume of 183.25K shares and market capitalization of 260.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 505 people. Harvard Bioscience Inc. CEO is James W. Green.
The one-year performance of Harvard Bioscience Inc. stock is 163.71%, while year-to-date (YTD) performance is 52.21%. HBIO stock has a five-year performance of 140.07%. Its 52-week range is between 2.06 and 7.14, which gives HBIO stock a 52-week price range ratio of 87.99%
Harvard Bioscience Inc. currently has a PE ratio of -27.30, a price-to-book (PB) ratio of 2.84, a price-to-sale (PS) ratio of 2.77, a price to cashflow ratio of 22.60, a PEG ratio of 2.32, a ROA of -4.65%, a ROC of -1.19% and a ROE of -9.43%. The company’s profit margin is -3.70%, its EBITDA margin is 5.10%, and its revenue ttm is $78.33 Million , which makes it $1.97 revenue per share.
Of the last four earnings reports from Harvard Bioscience Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Harvard Bioscience Inc.’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Harvard Bioscience Inc. is Moderate Buy (2), with a target price of $8, which is +22.51% compared to the current price. The earnings rating for Harvard Bioscience Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Harvard Bioscience Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Harvard Bioscience Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.41, ATR14 : 0.28, CCI20 : -0.79, Chaikin Money Flow : -0.18, MACD : -0.06, Money Flow Index : 36.83, ROC : 1.11, RSI : 52.45, STOCH (14,3) : 80.00, STOCH RSI : 1.00, UO : 49.71, Williams %R : -20.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Harvard Bioscience Inc. in the last 12-months were: Alan I. Edrick (Buy at a value of $105 000), James W. Green (Buy at a value of $50 600), James W. Green (Sold 35 000 shares of value $209 300 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.